Literature DB >> 28260073

FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression.

Runze Shang1, Meng Pu1, Yu Li2, Desheng Wang1.   

Abstract

The Forkhead box M1 (FOXM1) transcription factor plays crucial roles in the initiation and progression of various malignancies, including hepatocellular carcinoma (HCC). However, the mechanism by which FOXM1 regulates cancer metabolism remains unclear. In the present study, overexpression and RNA interference (RNAi) approaches were used to investigate the role of FOXM1 in the regulation of glycolysis in vitro. Luciferase reporter assays were used to explore the transcriptional regulation of the glucose transporter 1 (GLUT1) promoter by FOXM1. Then, immunohistochemical staining was used to examine the expression of FOXM1 and GLUT1 in 100 paired HCC and adjacent non-cancerous liver tissues. Chi-square test and logistic regression analysis were performed to evaluate the association between FOXM1 and GLUT1 expression with clinicopathological characteristics. Our data showed that FOXM1 promoted glycolysis in the HCC cells. FOXM1 knockdown significantly reduced the expression of GLUT1 among key glycolysis-related molecules in the different HCC cell lines. Glucose uptake and lactate production assay showed that FOXM1 positively regulated glycolysis based on GLUT1 expression. Moreover, FOXM1 overexpression increased and knockdown decreased GLUT1 expression. Luciferase reporter assays showed that the -206 to -199 bp region of the GLUT1 promoter is important for FOXM1 to enhance GLUT1 promoter activity. The results of the IHC analysis showed that the protein expression of FOXM1 and GLUT1 was closely related to the tumor histological grade and TNM stage. In addition, GLUT1 expression was also related to microvascular invasion. In conclusion, overexpression of FOXM1 and GLUT1 may play critical roles in HCC. FOXM1 promotes HCC glycolysis by transactivating GLUT1 expression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28260073     DOI: 10.3892/or.2017.5472

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.

Authors:  Qing Peng; Liyuan Hao; Yinglin Guo; Zhiqin Zhang; Jingmin Ji; Yu Xue; Yiwei Liu; Caige Li; Junlan Lu; Xinli Shi
Journal:  J Nat Med       Date:  2022-09-06       Impact factor: 3.192

2.  FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1.

Authors:  Qing Yang; Fang Wu; Yong Zhang; Rensheng Wang
Journal:  J Cell Mol Med       Date:  2022-06-03       Impact factor: 5.295

3.  Modulation of MnSOD and FoxM1 Is Involved in Invasion and EMT Suppression by Isovitexin in Hepatocellular Carcinoma Cells.

Authors:  Yebei Qiu; Xiaocheng Cao; Lihua Liu; Xiaozheng Cao; Qing Yuan; Xiang Li; Yinghong Cui; Chang Xu; Chang Zou; Kaiqun Ren; Jianguo Cao
Journal:  Cancer Manag Res       Date:  2020-07-14       Impact factor: 3.989

4.  The positive feedback between ACSL4 expression and O-GlcNAcylation contributes to the growth and survival of hepatocellular carcinoma.

Authors:  Jiachen Wang; Zhao Wang; Jiaxiang Yuan; Jiaxiang Wang; Xinsheng Shen
Journal:  Aging (Albany NY)       Date:  2020-05-01       Impact factor: 5.682

5.  FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer.

Authors:  Weixing Dai; Xianke Meng; Shaobo Mo; Wenqiang Xiang; Ye Xu; Long Zhang; Renjie Wang; Qingguo Li; Guoxiang Cai
Journal:  Cell Commun Signal       Date:  2020-01-09       Impact factor: 5.712

Review 6.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

7.  MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1.

Authors:  Shuguang Cao; Limiao Lin; Xuanping Xia; Hao Wu
Journal:  Oncotarget       Date:  2017-08-10

8.  Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Chaojie Liang; Jingyang Zhao; Hua Ge; Guangming Li; Jixiang Wu
Journal:  Onco Targets Ther       Date:  2018-06-19       Impact factor: 4.147

9.  Identification of FOXM1 as a specific marker for triple‑negative breast cancer.

Authors:  Yanli Tan; Qixue Wang; Yingbin Xie; Xiaoxia Qiao; Shun Zhang; Yanan Wang; Yongbin Yang; Bo Zhang
Journal:  Int J Oncol       Date:  2018-10-19       Impact factor: 5.650

10.  Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.

Authors:  Runze Shang; Miao Wang; Bin Dai; Jianbing Du; Jianlin Wang; Zekun Liu; Shibin Qu; Xisheng Yang; Jingjing Liu; Congcong Xia; Lin Wang; Desheng Wang; Yu Li
Journal:  Mol Oncol       Date:  2020-03-30       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.